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Background: Endogenous uveitis is a chronic inflammatory 
eye disease of human, which frequently leads to blindness. 
Experimental autoimmune uveoretinitis (EAU) is an animal 
disease model of human endogenous uveitis and can be in-
duced in susceptible animals by immunization with retinal 
antigens. EAU resembles the key immunological character-
istics of human disease in that both are CD4
＋ T-cell medi-
ated diseases. Dendritic cells (DCs) are specialized anti-
gen-presenting cells that are uniquely capable of activating 
naïve T cells. Regulation of immune responses through mod-
ulation of DCs has thus been tried extensively. Recently our 
group reported that donor strain-derived immature DC pre-
treatment successfully controlled the adverse immune re-
sponse during allogeneic transplantation. Methods: EAU was 
induced by immunization with human interphotoreceptor reti-
noid-binding protein (IRBP) peptide1-20. Dendritic cells were 
differentiated from bone marrow in the presence of recombi-
nant GM-CSF. Results: In this study, we used paraformalde-
hyde-fixed bone marrow-derived DCs to maintain them in an 
immature state. Pretreatment with fixed immature DCs, but 
not fixed mature DCs, ameliorated the disease progression 
of EAU by inhibiting uveitogenic CD4
＋ T cell activation and 
differentiation. Conclusion: Application of iBMDC prepared 
according to the protocol of this study would provide an im-
portant treatment modality for the autoimmune diseases and 
transplantation rejection.
[Immune Network 2011;11(6):399-405]
INTRODUCTION
Endogenous  uveitis  is  a  chronic  inflammatory  eye  disease, 
leading to blindness not infrequently (1). Even though, uveitis 
often  appears  in  association  with  systemic  diseases  such  as 
Vogt-Koyanagi-Harada  disease  or  Behcet’s  disease,  the  ma-
jority of uveitis is still of an idiopathic origin (2). Experimental 
autoimmune uveoretinitis (EAU) is a disease model of human 
endogenous uveitis and can be induced in susceptible animals 
by immunization with retinal antigens (3). Uveitogenic anti-
gens which can induce EAU are retinal soluble antigen, inter-
photoreceptor retinoid-binding protein (IRBP), rhodopsin, op-
sin, recoverin, and phosducin (4). EAU is a CD4
＋ T cell-medi-
ated disease. Uveitogenic effector CD4
＋ T cells infiltrate into 
the  eyes  and  are  responsible  for  the  pathogenesis  (5). 
    Dendritic  cells  (DCs)  are  specialized  antigen-presenting 
cells that are uniquely capable of activating naïve T cells (6). 
When pathogens invade the tissue, tissue-resident DCs endo-
cytose  antigens  and  process  them  for  presentation  on  the 
MHC molecules. With appropriate inflammatory signals pro-
voked by pathogens, DCs upregulated the expression of sur-
face  MHC  molecules  containing  antigenic  peptides  and 
co-stimulatory molecules on their surface (7). High level sur-
face expression of MHC class II and co-stimulatory molecules 
are  whole-mark  of  activated  dendritic  cells  and  are  pre-
requisite  for  effective  activation  of  naïve  CD4
＋ T  ce ll s (8 ). 
In contrast to activated DCs, immature DCs with low levels 
of MHC and co-stimulatory molecules have been implicated 
in the regulation of immune responses through diverse effec-
tor mechanisms (9). Particularly, immature DCs are able to 
induce a state of hyporesponsiveness in T cells, the phenom-
enon has been used for the control or suppression of the im-Maturation-Resistant DCs Ameliorate EAU
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mune  response  (10).  Therefore,  numerous  attempts  have 
been made to modify DCs to retain their immature phenotype 
for the induction of antigen-specific tolerance (11,12). Recent-
ly our group reported that donor strain-derived immature DC 
pretreatment  successfully  controlled  the  immune  response 
during  allogeneic  transplantation  (13). 
    In this study, we used paraformaldehyde-fixed bone mar-
row (BM)-derived DCs to maintain them in an immature state. 
Pretreatment with fixed immature DCs, but not fixed mature 
DCs,  ameliorated  the  disease  progression  of  experimental 
uveoretinitis by inhibiting uveitogenic CD4
＋ T cell activation 
and  differentiation.
MATERIALS AND METHODS
Animals and induction of EAU 
C57BL/6 (B6) female mice (Jackson, Bar Harbor, MA), 8-10 
weeks of age, were immunized s.c. in the both footpads and 
tail-base with 250μg of human interphotoreceptor retinoid- 
binding  protein  (IRBP)  peptide1-20 (G PT HL F QP SL VL DM A K V-
LLD) (Peptron, Daejeon, Korea) in 100μl of emulsion in com-
plete  Freund’s  a d j u v a n t  ( S i g m a - A l d r i c h ,  S t .  L o u i s ,  M O )  s u -
pplemented with Mycobacterium tuberculosis (strain H37 Ra; 
D i f c o ,  D e t r o i t ,  M I )  t o  1 . 5  m g / m l  ( 1 4 ) .  M i c e  w e r e  r e c e i v e d 
1.0μg of pertussis toxin (Sigma-Aldrich), intraperitoneally at 
the time of the immunization. All mice were bred and main-
tained in specific pathogen-free conditions at the animal fa-
cility of Seoul National University College of Medicine. All an-
imal experiments were performed with the approval of the 
Institutional  Animal  Care  and  Use  Committee  (IACUC,  SNU 
050502003)  at  Seoul  National  University.
Histopathological scoring
Eyes  were  removed  from  mice  sacrificed  21  days  after  the 
immunization  with  human  IRBP  peptide,  and  then  fixed  in 
4% buffered paraformaldehyde (PFA), embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin for histo-
pathological  analysis.  The  severity  of  the  disease  was  de-
termined for each eye and scored on a scale of 0∼4 in half- 
point increments according to a semiquantitative system (15). 
Generation of bone marrow-derived dendritic cells 
Bone marrow cells from the both femurs and tibias were ob-
tained from 6∼8-week-old mice. Cells were passed through 
a  nylon  mesh  and  red  blood  cells  were  lysed.  Following 
washing, granulocytes, B cells and red blood cell precursors 
were removed by magnetic beads (Miltenyi Biotec, Auburn, 
CA)  using  a  monoclonal  antibody  cocktail  of  anti-GR1,  an-
ti-TER119,  and  anti-B220.  5×10
5  cells/ml  were  plated  in 
24-well  plates  in  1  ml  of  medium  supplemented  with  20 
ng/ml recombinant granulocyte-macrophage colony-stimulat-
ing factor (rGM-CSF; BioSource, Camarillo, CA). The cultures 
were fed every 2 days by gently swirling the plates, aspirating 
50%  of  the  medium,  and  adding  fresh  medium  containing 
rGM-CSF. Dendritic cells (DCs) were harvested 6 days after 
bone-marrow  culture  by  removing  Gr1
＋  granulocytes  from 
cultures using magnetic beads. To induce maturation of DCs, 
1μg/ml lipopolysaccharide (Salmonella abortus equi; Sigma- 
A l d r i c h )  w a s  a d d e d  t o  t h e  c e l l  c u l t u r e  f o r  1 8  h r s  b e f o r e  
harvest. To render DCs maturation-resistant, they were fixed 
by resuspension in 2% (weight/volume) paraformaldehyde for 
10 min, then washed three times. Fixed immature or fixed 
m a t u r e  c e l l s  w e r e  u s e d  f o r  t h e  f o l l o w i n g  e x p e r i m e n t s .
IRBP-specific CD4
＋ T cell proliferation 
CD4
＋ T cells from draining inguinal and popliteal lymph no-
des  of  mice  were  purified  using  magnetic  beads  on  day  7 
after  immunization  with  human  IRBP  peptide,  then  co-cul-
tured (2×10
5 cells/well) with γ-irradiated, syngeneic spleno-
cytes (4×10
5 cells/well) with or without 30μM of IRBP pep-
tide in round-bottom 96 well plate. Culture was incubated for 
72 hrs at 37
oC in a 5% CO2 atmosphere, pulsed [
3H]- thymi-
dine  (1μCi/well)  during  the  last  12  hrs,  then  incorporated 
radioactivity  was  counted.
Migration of bone marrow-derived dendritic cells
In vitro generated DCs from bone marrow of GFP transgenic 
mice (Jackson, Bar Harbor, MA) were fixed in 2% PFA and 
injected intravenously with 5×10
6 cells into B6 mice. On 14 
days after injection with DCs, spleens and inguinal lymph no-
des were frozen in OCT compound, sectioned (4μm), and 
examined  under  fluorescence  microscopy. 
Intracellular cytokine staining and flowcytometric 
analysis 
After  restimulation,  the  cells  were  fixed  with  4%  paraf-
ormaldehyde  and  permeabilized  with  0.5%  Triton  X-100. 
Cells were stained with anti-CD4, anti-CD62L, and anti-IFN-γ 
(all from BD-Pharmingen, San Diego, CA). Flow cytometric 
analysis was conducted using a FACSCalibur (BD Bioscience, 
San  Jose,  CA).Maturation-Resistant DCs Ameliorate EAU 
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Figure 1. Mature-resistant DC ameliorates EAU in mice. (A) Histology of eyes. C57BL/6 (B6) 
mice were intravenously injected with 5×10
6 BM-derived fixed immature DCs (iBMDC), fixed
mature DCs (mBMDC), or media. Two days after the BMDC transfer, mice were immunized 
with human IRBP peptide1-20, Both eyes were removed, fixed in 4% paraformaldehyde, and 
embedded in paraffin. Sections (4μm) were prepared and stained with hematoxylin and eosin 
(original magnification, ×100). Midsagittal section for each eyes were used. V, vitreous; GL,
ganglion layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigmented 
epithelium (RPE); Ch, choroid. Retina folding and infiltrations (arrows). (B) Histopathological 
score of EAU. Data are presented as the mean±SEM of n=10 mice for each group from two 
independent experiments. (C) IRBP-specific proliferation of CD4
+ T cells. CD4
+ T cells from 
draining lymph nodes were purified with magnetic beads on the 7th day after immunization,
then co-cultured (2×10
5 cells/well) with irradiated, syngeneic splenocytes (4×10
5 cells/well) with
30 mM of IRBP peptide. The cultures were incubated for 3 days and pulsed with [
3H]-thymidine
(1 mCi/well) for the last 12 hrs. Data represent means±SD of two independent determinations
with draining lymph nodes from n=3 mice/group. 
RESULTS
Maturation-resistant DCs ameliorate EAU in mice
Female C57BL/6 (B6) mice were immunized with an uveito-
genic human IRBP 1∼20 peptide. Two days before immuni-
zation, mice were intravenously injected with 5×10
6 BM-de-
rived  fixed  immature  DCs  (iBMDC),  fixed  mature  DCs 
(mBMDC), or media. B6 mice pretreated with mBMDC devel-
oped more severe uveoretinitis compared with the moderate 
disease  in  media-pretreated  mice,  whereas  mice  pretreated 
with iBMDC revealed improved disease phenotype compared 
with  media-pretreated  control.  Extensive  tissue  damage,  in-
cluding retinal folding, heavy inflammatory cell infiltration in-
to  the  vitreous  humor,  and  choroidal  granuloma  formation 
were noted in the eyes of mBMDC-pretreated mice (Fig. 1A). 
In contrast to this, mice pretreated with iBMDC exhibited very 
mild inflammatory cell infiltration and local retinal destruction 
(Fig. 1A). The median disease scores were 1.8 (mBMDC-pre-
treated), 0.6 (iBMDC-pretreated), and 1.4 (media-pretreated) 
(Fig. 1B). IRBP-specific CD4
＋ T lymphocyte proliferation pre-
pared  from  the  draining  lymph  nodes  was  greatly  reduced 
in iBMDC-pretreated mice compared to the media-pretreated 
control  (Fig.  1C).
Pretreatment with immature DCs reduced the 
activation and differentiation of CD4
＋ T cells
To evaluate the initial uveitogenic CD4
＋ T cell responses fol-
lowing  immunization  in  the  mBMDC  or  iBMDC-pretreated 
mice, lymphocytes prepared from draining lymph nodes were 
analyzed on the 7th day after immunization for the activation 
marker. CD62L-negative activated T cells among CD4
＋ T cells 
w e r e  i n c r e a s e d  f o l l o w i n g  i m m u n i z a t i o n  w i t h  I R B P  p e p t i d e  Maturation-Resistant DCs Ameliorate EAU
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Figure 2. iBMDC-pretreatment reduced the acti-
vation of CD4
+ T cells. Draining lymph node 
cells from the mice pretreated with mBMDC, 
iBMDC, or media and immunized with human
IRBP peptide were harvested on the 7th day 
after immunization. T-cell activation was ana-
lyzed using flowcytometer after staining with 
anti-CD4 and anti-CD62L antibodies. The data 
are representative of three independent deter-
minations.
while iBMDC pretreatment decreased the percentage of acti-
vated CD4
＋ T cells compared to the media-pretreated control 
(Fig.  2). 
    Uveitogenic  CD4
＋ T  c e l l  d i f f e r e n t i a t i o n  i n  t h e  d r a i n i n g  
lymph  nodes  were  also  analyzed  on  the  7th  day  after 
immunization. IFN-γ-expressing CD4
＋ T cells among uveito-
genic T cells were decreased in the iBMDC-pretreated mice 
and increased in the mBMDC-pretreated mice compared with 
media-pretreated  control  mice  (Fig.  3).
Both immature and mature DCs migrate into the 
T-cell zone of the secondary lymphoid organs
To  evaluate  the  site  of  immunoregulation  on  the  activation 
and differentiation of uveitogenic CD4
＋ T cells implemented 
by  pretreated  iBMDC,  B6  mice  were  received  iBMDC  and 
mBMDC prepared from syngeneic GFP transgenic mice. On 
14 days after injection with DCs, spleens and inguinal lymph 
nodes were examined under fluorescence microscopy. Both 
the fixed immature DCs and fixed mature DCs migrated into 
the T-cell zones of secondary lymphoid organs such as spleen 
a n d  i n g u i n a l  l y m p h  n o d e s  a n d  s t a y e d  t h e r e  a t  l e a s t  f o r  1 4 
days  following  injection  (Fig.  4). 
DISCUSSION
In this study, we demonstrated that pretreatment with fixed 
immature bone marrow-derived dendritic cells (iBMDC) ame-
liorated experimental autoimmune uveoretinitis (EAU) by in-Maturation-Resistant DCs Ameliorate EAU 
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Figure 3. Intracellular cytokine expression of uveitogenic CD4
+ T cells. Draining lymph node cells were harvested
from the mice received mBMDC, iBMDC, or media on the 7th day after immunization with IRBP peptide and
were restimulated in vitro with PMA and ionomycin as described in Materials and Methods. Cells were analyzed
using flowcytometer after staining with anti-CD4 and anti-IFN-γ antibodies. The data are representative of two
independent determinations.
Figure 4. Both mBMDC and iBMDC migrate into T-cell zone of the
spleen and lymph nodes. B6 mice were received mBMDC and iBMDC
prepared from GFP transgenic mice. On 14 days after injection with
DCs, spleens and inguinal lymph nodes were frozen in OCT 
compound. Sections (4μm) were examined under fluorescence 
microscopy (original magnification, ×200). Spleen (A) and inguinal 
lymph node (B) from the mice received iBMDC. Spleen (C) and 
inguinal lymph node (D) from the mice received mBMDC. T cell zone
(T) and B cell zone (B) were indicated. 
hibiting  uveitogenic  CD4
＋ T  c e l l  a c t i v a t i o n  a n d  d i f f e r e n -
tiation. Pretreated fixed immature dendritic cells migrated into 
the  T-cell  zone  of  the  secondary  lymphoid  organs  and  af-
fected  the  uveitogenic  CD4
＋ T  c e l l  i m m u n e  r e s p o n s e s .
    EAU  is  an  animal  disease  model  of  human  endogenous 
uveitis  and  resembles  the  key  immunological  characteristics 
of human disease in that both are CD4
＋ T-cell mediated dis-
eases (5). In EAU pathogenesis, Th1 immune responses have 
been suggested to be essential factors. Susceptibility to dis-
ease  paralleled  Th1  responsiveness  among  the  different 
mouse or rat strains (16). In this study we found that pre-
treated  iBMDC  effectively  inhibited  uveitogenic  Th1  differ-
entiation  in  the  draining  lymph  nodes.  As  the  transferred 
fixed dendritic cells migrated and survived in the secondary 
lymphoid  organs for  more  than 2 weeks, we  assumed  that 
iBMDC directly inhibited initial uveitogenic CD4
＋ T cell acti-
vation  and  subsequent  differentiation  in  the  T-cell  zone  of 
these organs. Recently, Th17 cells have also been implicated 
in the disease progression of autoimmune eye diseases of hu-
man and animal models, including uveitis. Th17 cells among 
peripheral blood lymphocytes were increased in active uveitis 
patients and treatment with blocking anti-IL-17 antibody miti-
gated EAU in animal models (17). IFN-γ and IL-17 were sug-
gested  to  have  distinct  pathogenic  roles  in  different  animal 
models  of  autoimmune  uveoretinitis  uveiretinitis  (18,19). 
Thus, evaluation of the effect of iBMDC on the Th17 differ-
entiation  of  uveitogenic  CD4
＋ T  c e l l s  w o u l d  b e  v e r y  i m -
portant  in  the  following  study. 
  As the immature DCs are important in maintaining self tol-
erance, many researchers have tried to regulate autoimmune 
response  using  immature  DCs  (8).  However,  previous  at-
tempts have not obtained consistent results, possibly because 
the immaturity of transferred DCs have not sustained in vivo Maturation-Resistant DCs Ameliorate EAU
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and they mature spontaneously following injection and so can 
activate  the  immune  responses  (20,21).  To  overcome  this 
phenomenon, we treated DCs with paraformaldehyde to ren-
der them unable to change their phenotypes. We used 2% 
paraformaldehyde  as  the  fixative  agent  in  our  experiments 
because we successfully controlled allogeneic T cell response 
by  pretreating  iBMDC  prepared  according  to  this  protocol 
(13).  Pretreatment  of  iBMDC  also  ameliorated  experimental 
autoimmune  uveoretinitis  in  this  study,  while  mBMDC  pre-
treatment aggravated the disease. One caveat for this protocol 
of DC preparation was that fixation might have destroyed the 
ability of DCs to function as antigen presenting cells and/or 
affected the survival of DCs in the recipient. Paraformalde-
hyde fixation, however, did not eliminate the potential of DCs 
in supporting allogeneic T-cell proliferation (13). Also as both 
the fixed immature DCs and fixed mature DCs survived over 
2 weeks in the secondary lymphoid organs of the recipients, 
the concern of second possibility was ruled out. Thus, appli-
cation of iBMDC prepared according to the protocol of this 
study would provide an important treatment modality for the 
autoimmune  diseases  and  transplantation  rejection.   
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